Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/54449
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGuijarro, Luis G-
dc.contributor.authorCano-Martínez, David-
dc.contributor.authorToledo-Lobo, M Val-
dc.contributor.authorSanmartín Salinas, Patricia-
dc.contributor.authorChaparro, María-
dc.contributor.authorGómez-Lahoz, Ana M-
dc.contributor.authorZoullas, Sofía-
dc.contributor.authorRodríguez-Torres, Rosa-
dc.contributor.authorRomán, Irene D-
dc.contributor.authorSebastiá Monasor, Laura-
dc.contributor.authorRuiz-Llorente, Lidia-
dc.contributor.authorBoyano-Adánez, María del Carmen-
dc.contributor.authorGuerra, Ivan-
dc.contributor.authorIborra, Marisa-
dc.contributor.authorCabriada, José Luis-
dc.contributor.authorBujanda, Luis-
dc.contributor.authorTaxonera, Carlos-
dc.contributor.authorGarcía-Sánchez, Valle-
dc.contributor.authorMarín-Jiménez, Ignacio-
dc.contributor.authorBarreiro de Acosta, Manuel-
dc.contributor.authorVera, Isabel-
dc.contributor.authorMartín-Arranz, María Dolores-
dc.contributor.authorMesonero, Francisco-
dc.contributor.authorSempere, Laura-
dc.contributor.authorGomollón, Fernando-
dc.contributor.authorHinojosa, Joaquín-
dc.contributor.authorAlvarez-Mon, Melchor-
dc.contributor.authorGisbert, Javier P-
dc.contributor.authorOrtega, Miguel A-
dc.contributor.authorHernández-Breijo, Borja-
dc.contributor.authorOn Behalf Of The Predicrohn Study Group From Geteccu-
dc.date.accessioned2021-10-06T08:35:39Z-
dc.date.available2021-10-06T08:35:39Z-
dc.date.issued2021-09-30-
dc.identifier.citationBiomed Pharmacother.2021 Sep;(144):112239es_ES
dc.identifier.urihttps://hdl.handle.net/20.500.12530/54449-
dc.description.abstractInflammatory bowel diseases (IBD), represented by ulcerative colitis (UC) and Crohn's disease (CD), are characterized by chronic inflammation of the gastrointestinal tract, what leads to diarrhea, malnutrition, and weight loss. Depression of the growth hormone-insulin-like growth factor-1 axis (GH-IGF-1 axis) could be responsible of these symptoms. We demonstrate that long-term treatment (54 weeks) of adult CD patients with adalimumab (ADA) results in a decrease in serum IGF-1 without changes in serum IGF-1 binding protein (IGF1BP4). These results prompted us to conduct a preclinical study to test the efficiency of IGF-1 in the medication for experimental colitis. IGF-1 treatment of rats with DSS-induced colitis has a beneficial effect on the following circulating biochemical parameters: glucose, albumin, and total protein levels. In this experimental group we also observed healthy maintenance of colon size, body weight, and lean mass in comparison with the DSS-only group. Histological analysis revealed restoration of the mucosal barrier with the IGF-1 treatment, which was characterized by healthy quantities of mucin production, structural maintenance of adherers junctions (AJs), recuperation of E-cadherin and β-catenin levels and decrease in infiltrating immune cells and in metalloproteinase-2 levels. The experimentally induced colitis caused activation of apoptosis markers, including cleaved caspase 3, caspase 8, and PARP and decreases cell-cycle checkpoint activators including phosphorylated Rb, cyclin E, and E2F1. The IGF-1 treatment inhibited cyclin E depletion and partially protects PARP levels. The beneficial effects of IGF-1 in experimental colitis could be explained by a re-sensitization of the IGF-1/IRS-1/AKT cascade to exogenous IGF-1. Given these results, we postulate that IGF-1 treatment of IBD patients could prove to be successful in reducing disease pathology.es_ES
dc.language.isoenes_ES
dc.relation.isversionofPreprintes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectAdalimumabes_ES
dc.subjectIGF-1es_ES
dc.subjectInflammatory bowel diseaseses_ES
dc.subject.meshReceptor, IGF Type 1-
dc.subject.meshInflammatory Bowel Diseases-
dc.subject.meshBody Weight-
dc.titleRelationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involvedes_ES
dc.typeArtículoes_ES
dc.identifier.pubmedID34601192es_ES
dc.format.volume144es_ES
dc.format.page112239es_ES
dc.description.peerreviewedes_ES
dc.identifier.journalBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapiees_ES
dc.identifier.journalabbreviationBiomed Pharmacotheres_ES
dc.contributor.authoraffiliationServicio de Digestivo. Hospital Universitario de Fuenlabradaes_ES
dc.subject.decsReceptor IGF Tipo 1-
dc.subject.decsEnfermedades Inflamatorias del Intestino-
dc.subject.decsPeso Corporal-
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
Biomedicine Pharmacology.pdf5,29 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons